Alnylam Announces Additional Grant of Tuschl II Patent in Japan

Posted: April 4, 2010 at 5:49 am

Story Summary: (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the Japanese Patent Office has granted claims in a second patent application (JP Application Number 2006-317758) for the Tuschl II patent series, entitled aRNA Interference Mediating Small RNA Molecules. a In May 2008, the Japanese Patent Office granted a related set of claims in the Tuschl II patent series (JP 4 095 895). The Tuschl II patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Max Planck Innovation GmbH, the licensing agent for the Max Planck Society. Alnylamas IP position is comprised of fundamental, chemistry, delivery, and target patents and patent applications that the company believes are necessary for the development and commercialization of RNAi therapeutics. About Alnylam Intellectual Property (IP)Alnylamas IP estate includes issued, allowed, or granted fundamental patents in many of the worldas major pharmaceutical markets that claim the broad structural and functional properties of RNAi therapeutic products. These include, but are not limited to: the Crooke Patents (U. S. Patent Nos. 5,898,031, 6,107,094, 7,432,249, 7,432,250, 7,629,321 and EP 0928290) issued in over 15 countries and licensed exclusively from Isis Pharmaceuticals, Inc. to Alnylam for RNAi therapeutics, which cover compositions, methods, and uses of modified oligonucleotides, including double stranded RNAs, to inactivate a target mRNA mediated by a double stranded RNase, such as aRISC,a which is the cellular enzyme complex that mediates RNAi; the Glover a375 patent (EP 1230375), granted in July 2005, licensed exclusively to Alnylam from Cancer Research Technologies, Ltd. , and currently under appeal, which covers therapeutic uses of double-stranded RNA expressed from endogenous templates or expression vectors to mediate RNA interference in mammalian cells; the Kreutzer-Limmer I a719 patent (EP 1550719), owned by Alnylam and where the company has received a notification of aintent to granta, which covers siRNAs comprising 15-21 nucleotides in length stabilized by chemical linkages; the Kreutzer-Limmer I a235 patent (DE 10066235), granted in January 2008 and owned by Alnylam, which covers methods, uses, and medicaments of siRNAs, with a length between 15 and 49 nucleotides, expressed through a vector; the Kreutzer-Limmer I a945 patent (EP 1214945) granted in June 2005, currently under appeal, and owned by Alnylam, which covers compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides; the Kreutzer-Limmer I a167 patent (DE 10080167) granted in October 2007, currently under appeal, and owned by Alnylam, which covers pharmaceutical compositions and uses of siRNAs with a length between 15 and 49 nucleotides that target certain broad categories of mammalian genes; the Kreutzer-Limmer II a061 patent (EP 1352061), granted in May 2006 and owned by Alnylam, which covers therapeutic compositions, methods, and uses of siRNA and derivatives directed toward approximately 130 disease targets; the Tuschl I patent (EP 1309726), granted in December 2009, and exclusively licensed to Alnylam from the Max Planck Society, the Massachusetts Institute of Technology, and Whitehead Institute, which covers methods for using certain dsRNAs for RNAi; the Tuschl II a704 patent (U. S. Patent No. 7,078,196) issued in July 2006 and exclusively licensed to Alnylam from the Max Planck Society, which broadly covers methods of making siRNAs with or without chemical modifications; the Tuschl II a044 patent (EP 1407044), granted in January 2008 and exclusively licensed to Alnylam from the Max Planck Society, which broadly covers compositions, methods, and uses of siRNAs; the Tuschl II patent (JP 4 095 895) granted in May 2008 in Japan and exclusively licensed to Alnylam from the Max Planck Society, which broadly covers compositions, methods, uses, and systems of siRNAs; the Tuschl II patent (JP Application No. 2006-317758) granted in March 2010 in Japan and exclusively licensed to Alnylam from the Max Planck Society, which broadly covers compositions, methods, uses, and systems of siRNAs; the Tuschl II patent (Application No. 6,506,559), Kreutzer & Limmer, Glover, Li & Kirby, Pachuk, Tuschl, Hannon, Giordano, and Kay & McCaffrey, amongst others. In addition to fundamental patents, Alnylam is the exclusive licensee in the field of RNAi therapeutics for more than 175 issued chemistry patents owned or controlled by Isis Pharmaceuticals, Inc. broadly covering chemical modifications, including motifs and patterns of modifications of oligonucleotides, including RNAi therapeutics. These patents include: 2a-Ribose modifications of oligonucleotides (Cook, U. S. Patent Nos. In addition to fundamental and chemistry patents, Alnylam is also the exclusive licensee in the field of RNAi therapeutics for certain delivery patents, including those owned and controlled by Tekmira Pharmaceuticals Corporation, broadly covering delivery of oligonucleotides, including RNAi therapeutics, with liposomal formulations. 6,858,225); and, chemically modified siRNAs with adrug-likea properties for in vivodelivery (Soutschek and Manoharan, U. S. patent application 10/916,185 /Allowed). RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. About Alnylam PharmaceuticalsAlnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The companyas leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. Alnylam Forward-Looking StatementVarious statements in this release concerning Alnylamas future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In addition, any forward-looking statements represent Alnylamas views only as of today and should not be relied upon as representing its views as of any subsequent date….Read the Full Story

Related posts:

  1. Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics
  2. Alnylamas Kreutzer-Limmer I Patent Upheld in German Opposition Proceedings
  3. Alnylamas Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings


Related Post

Comments are closed.

Archives